Overview

• The analysis used Denmark’s national registries to follow 77,310 adults without diabetes who began semaglutide between December 1, 2022 and October 1, 2023.
• By three, six, and nine months, 18%, 31%, and 42% had stopped treatment, with more than half off the drug by one year.
• Higher discontinuation was linked to ages 18–29, residence in low‑income areas, male sex, prior gastrointestinal or psychiatric medication use, and cardiovascular or other chronic conditions.
• Researchers warned that stopping often reverses appetite control, making weight regain common and suggesting many users may require long-term therapy.
• The findings were presented at the European Association for the Study of Diabetes meeting, with noted limits including lack of individual BMI and payment data and undercapture of milder side effects.